Stockscreener 앱 받기
1.21
6.20%
-0.08
Pmv Pharmaceuticals Inc 주식(PMVP)의 최신 뉴스
PMV appoints Matt Eckler: what the 2027 filing means for PMV Pharmaceuticals stock - ad-hoc-news.de
PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals stock posts 21.60 percent YTD - ad-hoc-news.de
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Yahoo Finance
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity - Seeking Alpha
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter - AD HOC NEWS
PMV PHARMACEUTICALS APPOINTS MATT ECKLER, PH.D., TO BOARD OF DIRECTORS - Moomoo
PMV Pharmaceuticals Appoints Matt Eckler to Board Ahead of 2027 NDA Filing - citybiz
PMV Pharmaceuticals Director Matthew Joseph Eckler Granted 84,000 Stock Options - Kalkine Media
PMV Pharmaceuticals Appoints Matthew Joseph Eckler as Director; Files Initial Ownership Statement with SEC - Kalkine Media
Phase 2 single-drug enrollment is complete. PMV Pharma (PMVP) plans an ovarian cancer drug application. - Stock Titan
PMV Pharmaceuticals adds biotech investor to its board - StreetInsider
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - Yahoo Finance
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors - GlobeNewswire
A Q1 2027 application for accelerated approval is planned for PMV’s ovarian cancer drug. - Stock Titan
Biotech Stocks At 52-Week HighsKOD, MASS, OBIO, CDNA, PMVP - RTTNews
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Zacks Investment Research
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Yahoo Finance
An investor group in PMV Pharmaceuticals (NASDAQ: PMVP) is held just under a 10% stake by its warrant terms. - Stock Titan
PMV Pharma appoints Philip Herman as CCO - thepharmaletter.com
symbol__ Stock Quote Price and Forecast - cnn.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Australia
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - GlobeNewswire
PMVP SEC Filings, Jul-Aug 2025PMV Pharmaceuticals, Inc. Filing Archive - Stock Titan
PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de
PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - ad-hoc-news.de
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals (PMVP) Updates Interim Ovarian Cancer Trial Results Amid Valuation Challenges - GuruFocus
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks
PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView
PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com
PMV Pharmaceuticals Announces Updated Promising Rezatapopt - GlobeNewswire
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering - Yahoo Finance
Ovarian cancer trial reports a 46% response rate; FDA filing planned - Stock Titan
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial - Yahoo Finance
ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView
4.22%
자본화:
|
볼륨(24시간):